The global ALS therapeutics market is valued at USD 812 million in 2024 and is projected to reach USD 1,964 million by 2035, growing at an 11.5% CAGR. Growth is driven by innovations in genetic therapies, gene-silencing technologies, improved diagnostics, and increased disease awareness. Key players include Biogen, Ionis Pharmaceuticals, Amylyx Pharmaceuticals, and others developing disease-modifying treatments.

Antisense oligonucleotide (ASO) therapeutics are emerging as a promising treatment approach for rare genetic and neuromuscular disorders, with over 70 pharmaceutical companies actively developing 90+ pipeline therapeutics targeting specific genetic mechanisms.

Law firm investigating potential claims against Amylyx Pharmaceuticals regarding allegedly misleading statements about Relyvrio drug launch and patient demand during November 2022 to November 2023 period.

Law firm investigating potential claims against Amylyx Pharmaceuticals regarding allegedly misleading statements about Relyvrio drug launch and patient demand during November 2022-2023.

Amylyx Pharmaceuticals' stock rose over 10% this week after the company reported positive results from a phase 2 clinical trial of its drug AMX0035 for the rare genetic disorder Wolfram Syndrome. The treatment was well-tolerated and showed sustained improvement in pancreatic function, leading the company to plan discussions with the FDA about advancing the drug to phase 3 testing.

Amylyx Pharma (NASDAQ:AMLX) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 0 3 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 1 0 0 2M Ago 3 0 2 0 0 3M Ago 1 0 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $9.22, a high estimate of $32.00, and a low estimate of $3.00. Highlighting a 66.73% decrease, the current average has fallen from the previous average price target of $27.71. Interpreting Analyst Ratings: A Closer Look A comprehensive examination of how financial experts perceive Amylyx Pharma is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Andrew Fein HC Wainwright & Co. Maintains Buy $8.00 - Joel Beatty Baird Lowers Neutral $3.00 $4.00 Andrew Fein HC Wainwright & Co. Maintains Buy $8.00 - Andrew Fein HC Wainwright & Co. Maintains Buy $8.00 $8.00 Andrew Fein HC Wainwright & Co. Lowers Buy $8.00 $42.00 Neena Bitritto-Garg Deutsche Bank Lowers Buy $8.00 $36.00 Chris Shibutani Goldman Sachs Lowers Neutral $4.00 $40.00 Joel Beatty Baird Lowers Neutral $4.00 $37.00 Graig Suvannavejh Mizuho Raises Buy $32.00 $27.00 Key Insights: Action Taken: Responding to changing market ...Full story available on Benzinga.com

Amylyx Pharmaceuticals (AMLX) delivered earnings and revenue surprises of -291.67% and 21.74%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals are part of the Zacks top Analyst Blog.

Moderna (MRNA) and Bristol Myers (BMY) are in focus on pipeline and regulatory updates.

In the last three months, 6 analysts have published ratings on Amylyx Pharma (NASDAQ:AMLX), offering a diverse range of perspectives from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 2 0 0 Last 30D 1 0 0 0 0 1M Ago 2 0 2 0 0 2M Ago 1 0 0 0 0 3M Ago 0 0 0 0 0 Analysts have recently evaluated Amylyx Pharma and provided 12-month price targets. The average target is $10.67, accompanied by a high estimate of $32.00 and a low estimate of $4.00. Experiencing a 66.31% decline, the current average is now lower than the previous average price target of $31.67. Deciphering Analyst Ratings: An In-Depth Analysis The analysis of recent analyst actions sheds light on the perception of Amylyx Pharma by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Andrew Fein HC Wainwright & Co. Maintains Buy $8.00 $8.00 Andrew Fein HC Wainwright & Co. Lowers Buy $8.00 $42.00 Neena Bitritto-Garg Deutsche Bank Lowers Buy $8.00 $36.00 Chris Shibutani Goldman Sachs Lowers Neutral $4.00 $40.00 Joel Beatty Baird Lowers Neutral $4.00 $37.00 Graig Suvannavejh Mizuho Raises Buy $32.00 $27.00 Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...Full story available on Benzinga.com

The article discusses upcoming events and earnings reports that investors should watch, including the consumer price index report, Federal Reserve minutes,...

Amylyx (AMLX) makes a formal decision to remove its amyotrophic lateral sclerosis drug from the U.S. and Canadian markets. The company is expected to reduce its workforce by 70%. Its shares are trading up on the news.